Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

J.B. Vermorken,F. Peyrade,Jürgen Krauss,Ricard Mesia,Eva Remenar,T. Gauler,Ulrich Keilholz,Jean-Pierre Delord,Philippe Schafhausen,Jozsef Erfan,Tim H. Brümmendorf,Lara Iglesias,U Bethe,Christine Hicking,Paul Clement

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

2014

J.B. Vermorken
F. Peyrade
Jürgen Krauss
Ricard Mesia
Eva Remenar
T. Gauler
Ulrich Keilholz
Jean-Pierre Delord
Philippe Schafhausen
Jozsef Erfan
Tim H. Brümmendorf
Lara Iglesias
U Bethe
Christine Hicking
Paul Clement

Background Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy.

Keywords:

Carcinoma
Pathology
Fluorouracil
Medicine
Cetuximab
Cisplatin
Progression-free survival
Integrin
Head and neck squamous-cell carcinoma
Cilengitide
Internal medicine
Oncology
Epidermal growth factor receptor
Maintenance therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations